Related Experiment Video
Updated: May 31, 2026
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Inhibitory effect of 2'-o-methoxyethyl-modified antisense oligonucleotides targeting vascular endothelial growth
Yi-Bing Fu1, Ze-Qing Wen, Xing-Bo Zhao
1Department of Obstetrics and Gynaecology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China.
Background:
Ovarian cancers are often at an advanced stage at diagnosis because early detection is difficult. The poor prognosis of ovarian cancers highlights the crucial need to develop better therapeutic agents and strategies. The objective of this study was to investigate the inhibitory effects of a new modified antisense oligonucleotides targeting vascular endothelial growth factor A (VEGF-A) in SKOV3 ovarian cancer cells.
Methods:
Antisense oligonucleotides targeting VEGF-A was designed, synthesized and transfected into SKOV3 ovarian cancer cells. Western blotting and real-time RT-PCR were used to analyze the inhibitory effects of antisense oligonucleotides on VEGF-A protein and mRNA expression. Transwell matrix assay was used to detect cell migration inhibition.
Results:
The antisense oligonucleotides targeting VEGF-A significantly decreased VEGF-A protein and mRNA expression and inhibited cell migration in SKOV3 ovarian cancer cells.
Conclusions:
This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells. This new oligonucleotides may be a promising therapeutic agent for ovarian cancers.
Insights
New modified antisense oligonucleotides targeting vascular endothelial growth factor A (VEGF-A) effectively reduced VEGF-A expression and inhibited ovarian cancer cell migration. This offers a promising therapeutic strategy for ovarian cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Ovarian cancer diagnosis is often delayed, leading to advanced stages and poor prognosis.
- There is a critical need for novel therapeutic agents and strategies for ovarian cancer treatment.
- Vascular Endothelial Growth Factor A (VEGF-A) is a key target in cancer therapy.
Purpose of the Study:
- To investigate the efficacy of modified antisense oligonucleotides targeting VEGF-A.
- To evaluate the inhibitory effects on VEGF-A expression in SKOV3 ovarian cancer cells.
- To assess the impact on cancer cell migration.
Main Methods:
- Design and synthesis of modified antisense oligonucleotides targeting VEGF-A.
- Transfection of oligonucleotides into SKOV3 ovarian cancer cells.
- Analysis of VEGF-A protein and mRNA expression using Western blotting and real-time RT-PCR.
- Assessment of cell migration inhibition using Transwell matrix assay.
Main Results:
- Significant reduction in both VEGF-A protein and mRNA expression.
- Demonstrated inhibition of cell migration in SKOV3 ovarian cancer cells.
- The modified antisense oligonucleotides showed significant efficacy.
Conclusions:
- Modified antisense oligonucleotides targeting VEGF-A effectively decrease VEGF-A expression.
- These oligonucleotides inhibit cell migration in ovarian cancer cells.
- This approach represents a potential new therapeutic agent for ovarian cancers.
